Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Lips

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
European Journal of Radiology|October 27, 2019
Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?Bas H M van der Velden, Tycho Bismeijer, Sander Canisius, et al.
Breast Cancer Research and Treatment|November 14, 2023
The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch populationSena Alaeikhanehshir, Renée S J M Schmitz, Alexandra W van den Belt-Dusebout, et al.
Radiology|May 27, 2020
Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene ExpressionTycho Bismeijer, Bas H M van der Velden, Sander Canisius, et al.
Breast Cancer Research : BCR|October 29, 2011
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAnessEsther H Lips, Nadja Laddach, Suvi P Savola, et al.
Plos One|December 22, 2017
Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patientsMarcelo Sobral-Leite, Esther H Lips, Hayra de Andrade Vieira-Monteiro, et al.
NPJ Breast Cancer|December 10, 2020
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancerDaniele Giardiello, Iris Kramer, Maartje J Hooning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2019
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-BioscoreTessa G Steenbruggen, Maartje van Seijen, Liselore M Janssen, et al.
International Journal of Cancer|August 25, 2025
Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic statusRenée S J M Schmitz, Alexandra W van den Belt-Dusebout, Maartje van Seijen, et al.
BMC Cancer|October 21, 2016
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation studyEva Gross, Harm van Tinteren, Zhou Li, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|April 4, 2024
Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trialsSena Alaeikhanehshir, Madelon M Voets, Frederieke H van Duijnhoven, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
European Journal of Radiology|October 27, 2019
Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?Bas H M van der Velden, Tycho Bismeijer, Sander Canisius, et al.
Breast Cancer Research and Treatment|November 14, 2023
The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch populationSena Alaeikhanehshir, Renée S J M Schmitz, Alexandra W van den Belt-Dusebout, et al.
Radiology|May 27, 2020
Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene ExpressionTycho Bismeijer, Bas H M van der Velden, Sander Canisius, et al.
Breast Cancer Research : BCR|October 29, 2011
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAnessEsther H Lips, Nadja Laddach, Suvi P Savola, et al.
Plos One|December 22, 2017
Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patientsMarcelo Sobral-Leite, Esther H Lips, Hayra de Andrade Vieira-Monteiro, et al.
NPJ Breast Cancer|December 10, 2020
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancerDaniele Giardiello, Iris Kramer, Maartje J Hooning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2019
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-BioscoreTessa G Steenbruggen, Maartje van Seijen, Liselore M Janssen, et al.
International Journal of Cancer|August 25, 2025
Cause-specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio-economic statusRenée S J M Schmitz, Alexandra W van den Belt-Dusebout, Maartje van Seijen, et al.
BMC Cancer|October 21, 2016
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation studyEva Gross, Harm van Tinteren, Zhou Li, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|April 4, 2024
Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trialsSena Alaeikhanehshir, Madelon M Voets, Frederieke H van Duijnhoven, et al.
Pageof 13